Teva Pharma (TEVA) Announces U.S. Launch of Generic Beyaz

October 12, 2016 10:01 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) announced the launch of RAJANI (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.02 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg) in the United States. RAJANI, the generic equivalent of Beyaz, is an oral contraceptive, available in a 28-day blister pack dispenser, for use by women to:

  • prevent pregnancy;
  • treat symptoms of premenstrual dysphoric disorder (PMDD) in women choosing to use an oral contraceptive for contraception;
  • treat moderate acne for women at least 14 years old if the patient desires an oral contraceptive for birth control; and
  • raise folate levels in women who choose to use an oral contraceptive for contraception.

Teva is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. This product enhances Teva’s already comprehensive oral contraceptive portfolio.

Teva has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva generic product.

Beyaz® had annual sales of approximately $133 million in the U.S., according to IMS data as of July 2016.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Related Entities

Definitive Agreement

Add Your Comment